SG11201608414VA - Vegfr2/ang2 compounds - Google Patents
Vegfr2/ang2 compoundsInfo
- Publication number
- SG11201608414VA SG11201608414VA SG11201608414VA SG11201608414VA SG11201608414VA SG 11201608414V A SG11201608414V A SG 11201608414VA SG 11201608414V A SG11201608414V A SG 11201608414VA SG 11201608414V A SG11201608414V A SG 11201608414VA SG 11201608414V A SG11201608414V A SG 11201608414VA
- Authority
- SG
- Singapore
- Prior art keywords
- ang2
- vegfr2
- compounds
- ang2 compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000227P | 2014-05-19 | 2014-05-19 | |
| PCT/US2015/030275 WO2015179168A1 (en) | 2014-05-19 | 2015-05-12 | Vegfr2/ang2 compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608414VA true SG11201608414VA (en) | 2016-11-29 |
Family
ID=53264806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608414VA SG11201608414VA (en) | 2014-05-19 | 2015-05-12 | Vegfr2/ang2 compounds |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9580499B2 (en) |
| EP (1) | EP3145955A1 (en) |
| JP (1) | JP6074071B2 (en) |
| KR (1) | KR20160138312A (en) |
| CN (1) | CN106795218A (en) |
| AP (1) | AP2016009552A0 (en) |
| AR (1) | AR100271A1 (en) |
| AU (1) | AU2015264552A1 (en) |
| BR (1) | BR112016023635A2 (en) |
| CA (1) | CA2945157A1 (en) |
| CL (1) | CL2016002891A1 (en) |
| EA (1) | EA201691901A1 (en) |
| IL (1) | IL248401A0 (en) |
| MA (1) | MA40013A (en) |
| MX (1) | MX2016015149A (en) |
| PE (1) | PE20161397A1 (en) |
| PH (1) | PH12016502298A1 (en) |
| SG (1) | SG11201608414VA (en) |
| TN (1) | TN2016000451A1 (en) |
| TW (1) | TW201605894A (en) |
| WO (1) | WO2015179168A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100270A1 (en) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | ANTIBODIES ANG2 |
| AR103477A1 (en) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | VEGFA / ANG2 COMPOUNDS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR101224468B1 (en) * | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
| DE102010003225A1 (en) * | 2010-03-24 | 2011-09-29 | Sennheiser Electronic Gmbh & Co. Kg | In-ear monitor system and method for controlling an in-ear monitor system |
| AR080794A1 (en) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| LT2681244T (en) * | 2011-03-02 | 2018-02-12 | Roche Glycart Ag | Cea antibodies |
-
2015
- 2015-05-04 AR ARP150101339A patent/AR100271A1/en unknown
- 2015-05-05 TW TW104114317A patent/TW201605894A/en unknown
- 2015-05-12 US US14/709,511 patent/US9580499B2/en not_active Expired - Fee Related
- 2015-05-12 PE PE2016002143A patent/PE20161397A1/en not_active Application Discontinuation
- 2015-05-12 AU AU2015264552A patent/AU2015264552A1/en not_active Abandoned
- 2015-05-12 KR KR1020167031967A patent/KR20160138312A/en active Search and Examination
- 2015-05-12 MA MA040013A patent/MA40013A/en unknown
- 2015-05-12 MX MX2016015149A patent/MX2016015149A/en unknown
- 2015-05-12 BR BR112016023635A patent/BR112016023635A2/en not_active Application Discontinuation
- 2015-05-12 AP AP2016009552A patent/AP2016009552A0/en unknown
- 2015-05-12 WO PCT/US2015/030275 patent/WO2015179168A1/en active Application Filing
- 2015-05-12 EP EP15724469.0A patent/EP3145955A1/en not_active Withdrawn
- 2015-05-12 EA EA201691901A patent/EA201691901A1/en unknown
- 2015-05-12 CA CA2945157A patent/CA2945157A1/en not_active Abandoned
- 2015-05-12 TN TN2016000451A patent/TN2016000451A1/en unknown
- 2015-05-12 SG SG11201608414VA patent/SG11201608414VA/en unknown
- 2015-05-12 JP JP2015563167A patent/JP6074071B2/en not_active Expired - Fee Related
- 2015-05-12 CN CN201580025685.8A patent/CN106795218A/en active Pending
-
2016
- 2016-10-19 IL IL248401A patent/IL248401A0/en unknown
- 2016-11-14 CL CL2016002891A patent/CL2016002891A1/en unknown
- 2016-11-17 PH PH12016502298A patent/PH12016502298A1/en unknown
-
2017
- 2017-01-17 US US15/407,389 patent/US20170121411A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6074071B2 (en) | 2017-02-01 |
| WO2015179168A1 (en) | 2015-11-26 |
| AR100271A1 (en) | 2016-09-21 |
| EP3145955A1 (en) | 2017-03-29 |
| EA201691901A1 (en) | 2017-04-28 |
| US20150329626A1 (en) | 2015-11-19 |
| IL248401A0 (en) | 2016-11-30 |
| BR112016023635A2 (en) | 2017-10-17 |
| PE20161397A1 (en) | 2016-12-28 |
| MA40013A (en) | 2015-11-26 |
| CN106795218A (en) | 2017-05-31 |
| PH12016502298A1 (en) | 2017-02-13 |
| TN2016000451A1 (en) | 2018-04-04 |
| US20170121411A1 (en) | 2017-05-04 |
| MX2016015149A (en) | 2017-03-07 |
| TW201605894A (en) | 2016-02-16 |
| AU2015264552A1 (en) | 2016-10-27 |
| JP2016531084A (en) | 2016-10-06 |
| KR20160138312A (en) | 2016-12-02 |
| CL2016002891A1 (en) | 2017-06-23 |
| CA2945157A1 (en) | 2015-11-26 |
| US9580499B2 (en) | 2017-02-28 |
| AP2016009552A0 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| IL248991A0 (en) | Substituted dihydroisoquinolinone compounds | |
| GB201415573D0 (en) | Compounds | |
| GB201411418D0 (en) | Compounds | |
| GB201410430D0 (en) | Compounds | |
| GB201402431D0 (en) | Compounds | |
| GB201417369D0 (en) | Compounds | |
| GB201416186D0 (en) | Compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201406956D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201412660D0 (en) | Compounds | |
| GB201417168D0 (en) | Compounds | |
| IL248401A0 (en) | Vegfr2/ang2 compounds | |
| GB201407695D0 (en) | Compounds | |
| GB201707862D0 (en) | Tracers | |
| GB2530305B (en) | Tracers | |
| GB201418365D0 (en) | Tracers | |
| GB201409664D0 (en) | Tracers | |
| GB201405361D0 (en) | Compounds | |
| GB201416116D0 (en) | Compounds | |
| GB201415570D0 (en) | Compounds | |
| GB201415571D0 (en) | Compounds | |
| GB201413527D0 (en) | Compounds |